Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXN NASDAQ:NLSP NASDAQ:PTIX NYSEAMERICAN:SVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$8.28-1.1%$8.63$6.51▼$13.27$8.87M1.6512,224 shs957 shsNLSPNLS Pharmaceutics$2.16-1.8%$2.25$1.30▼$15.59$7.91M0.18293,242 shs172,763 shsPTIXAtrinsic$3.24-3.9%$3.91$2.35▼$15.54$1.98M0.34188,883 shs115,097 shsSVTServotronics$46.94$44.71$9.67▼$47.48$120.17M1.4912,160 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics+2.81%-5.21%-3.52%+11.51%+3.08%NLSPNLS Pharmaceutics+2.33%-2.22%-5.58%+46.67%+1,051.83%PTIXAtrinsic+0.90%-2.32%-5.60%+12.06%-68.32%SVTServotronics0.00%0.00%-0.02%+333.43%+342.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics1.816 of 5 stars3.53.00.00.00.00.80.6NLSPNLS PharmaceuticsN/AN/AN/AN/AN/AN/AN/AN/APTIXAtrinsic0.1113 of 5 stars0.02.00.00.00.01.70.0SVTServotronicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00262.54% UpsideNLSPNLS Pharmaceutics 0.00N/AN/AN/APTIXAtrinsic 0.00N/AN/AN/ASVTServotronics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$460K19.07N/AN/A$10.37 per share0.80NLSPNLS PharmaceuticsN/AN/AN/AN/A($0.37) per shareN/APTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/ASVTServotronics$44.92M2.68$0.07 per share658.77$9.20 per share5.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics$8.02M-$0.34N/A∞N/A3,584.49%-54.27%-49.15%9/1/2025 (Estimated)NLSPNLS Pharmaceutics-$1.98MN/A0.00∞N/AN/AN/AN/A8/15/2025 (Estimated)PTIXAtrinsic-$5.53M-$13.11N/A∞N/AN/A-860.52%-354.19%8/12/2025 (Estimated)SVTServotronics-$1.62M$0.05N/A∞N/A-2.32%-1.23%-0.82%8/6/2025 (Estimated)Latest PTIX, SVT, ADXN, and NLSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025PTIXAtrinsicN/A-$2.75N/A-$2.75N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/ANLSPNLS PharmaceuticsN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/ASVTServotronicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A3.023.02NLSPNLS PharmaceuticsN/A2.692.69PTIXAtrinsicN/A0.860.86SVTServotronicsN/A3.461.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%NLSPNLS PharmaceuticsN/APTIXAtrinsic7.97%SVTServotronics24.77%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%NLSPNLS Pharmaceutics16.40%PTIXAtrinsic35.00%SVTServotronics33.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableNLSPNLS Pharmaceutics63.60 million3.01 millionNot OptionablePTIXAtrinsic2590,000383,000Not OptionableSVTServotronics2702.56 million1.69 millionNot OptionablePTIX, SVT, ADXN, and NLSP HeadlinesRecent News About These CompaniesTransDigm successfully acquires Servotronics in $134M dealJuly 2, 2025 | bizjournals.comServotronics, Inc. (SVT) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comTransDigm completes $134 million Servotronics dealJuly 2, 2025 | buffalonews.comBTransDigm and Servotronics Announce Successful Completion of Tender Offer and TransDigm's Acquisition of ServotronicsJuly 1, 2025 | prnewswire.comStar Equity Fund’s Successful Servotronics Campaign Leads to Acquisition by TransDigm for $47 per ShareJune 30, 2025 | finance.yahoo.comShareholder withdraws court filings seeking to block Servotronics acquisitionJune 20, 2025 | bizjournals.comServotronics shareholder seeks to block TransDigm acquisitionJune 18, 2025 | bizjournals.comTransDigm Group Incorporated acquiring Servotronics, Inc.June 8, 2025 | magnoliareporter.comMInside the bidding war for ServotronicsJune 7, 2025 | buffalonews.comBServotronics Says TransDigm Sweetens Acquisition Offer To $47/Share, Amends AgreementMay 31, 2025 | nasdaq.comServotronics Deal Rewrite Ignites Shareholder ValueMay 29, 2025 | insidermonkey.comServotronics, Inc.: Servotronics Executes Amendment to the Agreement and Plan of Merger with TransDigmMay 29, 2025 | finanznachrichten.deServotronics stock soars on raised takeover bidMay 29, 2025 | za.investing.comServotronics Executes Amendment to the Agreement and Plan of Merger with TransDigmMay 29, 2025 | finance.yahoo.comServotronics Shares Jump Nearly 25% on Upgraded Buyout Offer from TransDigmMay 29, 2025 | msn.comTransDigm raises offer price for Servotronics to $47/shareMay 29, 2025 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of ShareholdersMay 29, 2025 | morningstar.comMAskeladden Capital Presents Plan To Maximize AstroNova’s Shareholder ValueMay 23, 2025 | usatoday.comServotronics investor withdraws proxy campaign after acquisition dealMay 22, 2025 | bizjournals.comSERVOTRONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Servotronics, Inc. - SVTMay 21, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTIX, SVT, ADXN, and NLSP Company DescriptionsAddex Therapeutics NASDAQ:ADXN$8.28 -0.10 (-1.14%) As of 02:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.NLS Pharmaceutics NASDAQ:NLSP$2.16 -0.04 (-1.82%) Closing price 04:00 PM EasternExtended Trading$2.17 +0.01 (+0.46%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Atrinsic NASDAQ:PTIX$3.24 -0.13 (-3.86%) Closing price 04:00 PM EasternExtended Trading$3.23 -0.01 (-0.19%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Servotronics NYSEAMERICAN:SVT$46.94 0.00 (0.00%) As of 07/1/2025Servotronics, Inc. designs, manufactures, and markets servo-control components and other technology products for aerospace, military, and medical applications in the United States and internationally. It offers high-performance servo valves, including torque motor, hydraulic, and pneumatic valves. The company offers its products to products are sold to commercial aerospace, government, medical, and industrial markets. The company was incorporated in 1959 and is headquartered in Elma, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
